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1. Introduction 
Existing radioimmunoassay (RIA) procedures 
have the advantage of extreme sensitivity, but depend 
on the availability of a suitable radiolabeled ligand 
and of expensive equipment. Furthermore, such RIAs 
require a time-consuming phase-separation step [ 11. 
Several approaches have been suggested to overcome 
the drawbacks of RIA while retaining the specificity 
of an immunoassay [2-41, but the procedures pro- 
posed thus far suffer from inadequate sensitivity. We 
have explored the possibility of using chemilumines- 
cent markers, since chemlluminescent compounds 
are commonly detectable at pM levels [5-71. 
In the method described here, an isoluminol 
derivative is attached covalently to a carboxy deriva- 
tive of a steroid. The resulting steroid-chemilumines- 
cent marker conjugate emits light upon oxidation with 
hematin compounds and HzOz. When the steroid- 
chemiluminescent marker conjugate is bound to a 
specific binding protein, the total light production of 
the conjugate is enhanced. This binding and the conse- 
quent enhancement of light emission is prevented by the 
addition of unaltered steroid in a competitive manner. A 
‘homogeneous’ immunoassay, viz. one requiring no 
separation of bound and free hormone, can thus be 
designed. To illustrate this approach, the results of an 
immunoassay for plasma progesterone based on the 
monitoring of chemiluminescence are reported in the 
following sections. 
2. Materials and metnoas 
2.1 .Reagents 
Progesterone-l u-hemisuccinate (4-pregnene-3,20- 
ElsevierlNorth-Holland Biomedical Press 
dione-1 la-hemisuccinate) was purchased from 
Steraloids, Wilton, NH; Microperoxidase (MP-II), 
carbodiimide, N-hydroxysuccinimide , bovine serum 
albumin (fraction V) (BSA) from Sigma, St. Louis, 
MO; luminol [S-amino-2,3dihydrophthalazine-1,4- 
dione] from Aldrich Chemicals, Milwaukee, WI; 
DEAE-cellulose from Whatman, England; and 30% 
hydrogen peroxide solution from Merck, FRG. 
Antiserum to progesterone was raised in rabbits, 
using a progesterone-l o-hemlsuccinate-bovine 
serum albumin conjugate as the immunogen [8]. 
Anti-progesterone IgG fraction was prepared by 
ammonium sulfate precipitation, followed by 
DEAE-52 cellulose column chromatography [9] and 
dialysis against phosphate buffered saline (PBS). The 
titer and specificity of anti-progesterone IgG frac- 
tion were determined by radioimmunoassay proce- 
dures [8], using 0.05 M Tris (pH 8) containing 0.1 M 
NaClandO.l%NaNs,asthe assaybuffer.The amount 
of specific antibody in 1% IgG solution, determined 
according to [lo], was 0.8 mg/ml. 
The assay buffer in the chemiluminescent reac- 
tions was 0.02 M phosphate @H 8.6) containing 
0.01% BSA. 
Stock solutions of steroids and chemiluminescent 
compounds were prepared in ethanol and diluted to 
the desired concentration in assay buffer when 
required. 
Microperoxidase was dissolved at 1 mg/ml in 
0.01 M Tri-HCl (pH 7.4); this stock solution was 
kept at 4°C. The working solution was obtained by 
diluting the stock solution in assay buffer to 1 /.&I 
enzyme. 
The oxidant solution was prepared by adding 
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100 ~130% HzOz solution to 5 ml borate buffer 
(pH 8.6,0.06 M). 
2.2. Synthesis of 6- {N-ethyl-N (6-(4-pregnene-3,20- 
dione-lla-hemisuccinylamido)-hexyl)amino } 
2,3_dihydrophthalazine-1,4-dione (progesterone- 
AHEI conjugate) 
The progesterone-AHEI conjugate was synthe- 
sized in two steps. 
1. The hemisuccinate derivate of 1 la-hydroxy pro- 
gesterone (compound I, fig.1) was converted to an 
activated N-succinimide ester (compound II, fig.1). 
2. The activated ester was reacted with an equivalent 
amount of 6 [N-(6-aminohexyl)N-ethyl] -amino- 
2,3dihydrophthalazine-I ,4-dione (AHEI) [7], in 
the presence of two equivalents of sodium bicarbo- 
nate. 
The resulting progesterone-AHEI conjugate (com- 
pound III, fig.1) was separated by chromatography 
on silica Gel 60 and crystallized: m.p. 155-157°C; 
mass spectrum, m/e 7 14 (M’); ultraviolet absorption 
peaks at 241 nm (E 16 000), 294 nm (E 16 200) and 
320 nm (E 7200). 
COOH 
Fig.1. Reaction sequence for the synthesis of progesterone- 
amlnohexylethyl isoluminol (AHEI) conjugate; CD1 = car- 
bodiimide. 
2.3. Light measurements 
Measurements of total light emission were made 
with a custom-built instrument. The reaction vessel 
(6 X 50 mm disposable test tubes, Kimble, Toledo, 
OH) was placed in a light-tight housing over the 
aperture of a photomultiplier (PM 270 C, Inter- 
national Light, Newburyport, MA). Each tube con- 
tained the chemiluminescent compound and the 
reagents specified in 40 ~1. The light generating reac- 
tion was initiated by rapid injection of 100 1.11 oxidant 
with an Eppendorf pipette mounted on the cover of 
the light-tight compartment. The output of the photo- 
multiplier was measured simultaneously with a 
research radiometer (International Light, Model 700 
with power supply Model 760) reading in W/cm2 and 
with a storage oscilloscope (Type 543, Tektronix, 
Beaverton, OR) connected to the radiometer, reading 
in mV. The area under the curve traced by the 
oscilloscope was integrated. All reactions were done 
in quadruplicate; the mean values and their standard 
errors are reported. 
3. Results 
3.1. Determination of chemiiuminescent markers 
To determine optimal conditions, the oxidation of 
luminol with H202 was studied in various buffers and 
with different heme catalysts (e.g., microperoxidase, 
horse radish peroxidase). The microperoxidase-H202 
oxidation system at pH 8.6 afforded the most sensitive 
system for detection of luminol. The total light pro- 
duction measured within 0.1 s after addition of the 
oxidant increased linearly with luminol concentration 
and the lower limit of detection was -0.1 fmol/tube. 
When the isoluminol derivative 6 [N(6aminohexyl)- 
N-ethyl] -amino-2,3dihydrophthalazine-I ,4-dione 
(AHEI) was oxidized with the microperoxidase-H202 
system, the total light yield was 20% that of free 
luminol. The total light yield of AHEI relative to 
luminol was further reduced after covalent attach- 
ment to progesterone-l cu-hemisuccinate, and the 
limit of detection of progesterone-AHEI conjugate 
(compound III, fig.l) was 0.14 pmol/tube. 
3.2. Effect of anti-progesterone IgG on the light yield 
duringoxidation ofprogesterone-AHEIconjugate 
Varying levels of the y-immunoglobulin fraction 
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Fig.2. Effect of anti-progesterone IgG concentration on the 
total light yield from progesterone-AHEI conjugate. Varying 
levels of anti-progesterone IgG were incubated for 30 min at 
4’C with 0.2 pmol progesterone-AHEI in a total volume of 
30plassay buffer. Microperoxidaae (10 ~1 of a 1 PM solution) 
was added, the reaction vessel was mounted in the light-tight 
compartment, and 100 ~1 of the oxidant solution was injected. 
Oscilloscope measurements of light emission was started 
within 0.1 s after addition of the oxidant and measured for 1 s. 
(IgG) of an antiserum to progesterone-l la-hemi- 
succinate-bovine serum albumin were incubated for 
30 min at 4°C with 0.2 pmol progesterone-AHEI. 
Figure 2 shows the total light produced by the con- 
jugate upon oxidation as a function of the concentra- 
tion of the antiserum. The total light yield increased 
with increasing anti-progesterone IgG concentrations 
up to 6.2 pmol IgG/tube (Cfold light emission), but 
remained constant at higher concentrations. Heterol- 
ogous IgG, e.g., IgG from anti-cortisol sera, did not 
enhance light production (data not shown). 
In additional experiments, varying levels of pro- 
gesterone-AHEI conjugate were incubated with or 
without a futed amount of anti-progesterone IgG 
(6.2 pmol/tube) for 30 min at 4°C (fig.3). In the 
absence of anti-progesterone IgG, the total light yield 
produced by oxidation of progesterone-AHEI 
increased linearly with the concentration of conjugate 
up to 1.4 ng/tube. When anti-progesterone IgG was 
added, the total light yield increased linearly with the 
concentration ofprogesterone-AHEI up to 0.5 ng/tube 
(fig.3). The antibody-induced enhancement over this 
Fig.3. Effect of progesterone-AHEI conjugate concentration 
on IgGenhanced light emission. Reaction mixtures containing 
various levels of progesterone-AHEI conjugate in 30 ~1 assay 
buffer were incubated at 4°C for 30 min with (0) or without 
(A) 6.2 pmol anti-progesterone IgG. Further treatment as 
described in legend to fig.2. 
range was 4-fold. There was no further antibody- 
induced light increment, indicating saturation of the 
antibody. 
3.3. Validation of the progesterone immunoassay 
Competitive binding reactions were carried out by 
incubating varying levels of free progesterone with a 
constant amount of anti-progesterone IgG for 15 min 
at 37°C and 30 min at 4°C. The enzyme solution and 
the progesterone-AHEI conjugate were then added 
and after a brief incubation (30 s) at 4”C, the oxidant 
was injected. The light yield measured over 1 s 
decreased linearly with increasing progesterone con- 
centration over 25-400 pg/assay tube. Figure 4 
shows a composite standard curve obtained from 
four consecutive assays. The sensitivity of the assay 
was -25 pg/assay tube, but is capable of further 
improvement (unpublished ata). 
The specificity of the immunoassay using anti- 
progesterone IgG and chemiluminescence was similar 
to that observed when using the same anti-serum in a 
radioimmunoassay. Light emission was unaffected by 
addition of cortisol or estradiol. Minor crossreaction 
was observed with 17o-hydroxyprogesterone (1.5%), 
testosterone (2%) 1 la-hydroxyprogesterone (17%) 
and 1 l/3-hydroxyprogesterone (23%). 
A pool of human male plasma was serially diluted 
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Flg.4. A standard curve for progesterone measured by 
chemiluminescence immunoassay. Varying levels of free 
progesterone were incubated with 6.2 pmol anti-progesterone 
IgG ln a totalvolume of 20 ~1 assay buffer for 15 mm at 37°C 
and 30 mm at 4’C.T. he enzyme (10 rl of a 1 ~Msolution) 
and the progesterone-AHEI conjugate (140 pg in 10 ~1 
assay buffer) were then added, and after brief incubation 
(30 s) at 4’C, the oxidant was injected, Shown are mean 
values * SEM (n = 4). 
with the assay buffer and extracted with petroleum 
ether. The extracts were then assayed for progesterone 
by ~he~u~escence imm~oas~y . The regression 
of dilution factor on measured progesterone 
content was linear b= 160.2 x + 7.3) and the correla- 
tion coefficient was r = 0.994, 
Several plasma samples from non-pregnant women 
taken at different stages of the menstrual cycle (n = 15) 
were extracted with petroleum ether, and the extracts 
were assayed for progesterone by radioimmunoassay 
and by chemiluminescence immunoassay, using the 
same antiserum. The results of the two methods 
agreed well: I = 0.974;~ = 0.48 + 0.89 x, where y 
corresponds to values determined by radioimmuno- 
assay (fIg.5). 
4. Diiuaaion 
The progesterone assay described oes not require 
204 
8- 
7- 
I I I I I I I I I 
I 2 3 4 5 6 7 8 9 IO 
chemilumkasence immunoassoy(ng/ml) 
Fig.5. Comparison of plasma progesterone levels as deter- 
mined by RIA or by chemiluminescence immunoassay. 
physical separation of bound and free ligand, radio- 
activity counting or expensive quipment and can be 
accomplished in 50 min. The sensitivity achieved 
(25 pg/tube) is comparable to that obtained by radio- 
immunoassay, and is satisfactory for the measurement 
of progesterone innormal plasma. Furthermore, the 
steroid-chemiluminescent marker conjugate is stable 
at room temperature, can be characterized by physical 
methods and can be determined in < 1 s. 
The chemiluminescence immunoassay developed 
for progesterone is simple: it consists of only four 
reagents, viz. the oxidant, the enzyme, the steroid- 
chemiluminescent marker conjugate and the specific 
binding protein, in addition to the sample to be deter- 
mined. 
Although at this stage recording of the light pro- 
duction is made manually, the assay is amenable to 
automation. The method eliminates the health 
hazards and isotope disposal problems of RIA. 
Che~u~escen~e ~munoa~ys are likely to be 
particularly useful in small clinical aboratories and in 
developing countries, where isotope counting equip- 
ment is not readily available, and in larger centers 
where rapid results are desired. 
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